You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody with an upfront payment of $25 million, with the potential for additionaAlready a subscriber Login You have read all your…
The Swedish company has won the backing of the investment company Blue, which has placed an additional SEK 10 million investment (together with investments from the executives at the company) in the company following an earlier round of SEK93 million announced in April this year. The capital intaAlready a subscriber…
Oncopeptides has announced that the European Commission has granted Pepaxti marketing authorization in combination with dexamethasone. The approval concerns the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractoryAlready a subscriber Login You have read all your free…
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.Already a subscriber Login You have read all your free…
